28 July 2026
Dyne Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DYNE-302, enabling the company to begin a Phase 1 clinical trial in people living with facioscapulohumeral muscular dystrophy (FSHD). This marks the first time the investigational therapy will be tested in humans.
Clinical trial receives regulatory clearance
Dyne Therapeutics has received FDA clearance to begin a Phase 1 clinical trial of DYNE-302, an investigational therapy being developed for FSHD. The regulatory decision allows the company to start testing the investigational drug in people for the first time, representing an important milestone in the development of potential therapies for the condition.
An FDA clearance of an IND application does not indicate that an investigational drug has been proven safe or effective. Rather, it means the regulator has reviewed the available preclinical and manufacturing information and has determined that the proposed clinical study can proceed.
About the investigational therapy
DYNE-302 is designed to target DUX4, a gene that researchers believe plays a central role in the development of FSHD. The therapy uses small interfering RNA (siRNA) technology, which is intended to suppress the production of DUX4 in muscle cells. Researchers hope that reducing DUX4 activity may help prevent or reduce the muscle damage associated with the disease.
This study is part of a growing number of investigational approaches aimed at addressing the underlying biological mechanisms that contribute to FSHD, rather than focusing solely on symptom management.
Understanding DUX4 and FSHD
DUX4 is normally switched off in healthy muscle tissue. In people living with FSHD, however, the gene becomes active when it should remain silent. Researchers believe that this abnormal activation contributes to muscle damage and progressive weakness over time.
For this reason, many FSHD research programmes are exploring ways to reduce or switch off DUX4 activity. DYNE-302 is one of several investigational therapies being developed with this goal in mind.
Details of the clinical trial
The upcoming study is a Phase 1 clinical trial, the earliest stage of testing a new investigational therapy in people. According to information released by the company, the study will be a randomised, placebo-controlled, double-blind, multiple ascending dose trial involving ambulatory adults with FSHD.
The first participant cohort is expected to include nine individuals, with six receiving DYNE-302 and three receiving placebo. The primary objectives of the trial are expected to focus on safety, tolerability and how the therapy behaves within the body.
The company has not yet reported any human clinical results for DYNE-302. No information about trial locations has been provided in the materials reviewed.
Significance for the FSHD community
For people living with FSHD, the FDA clearance represents another sign of continued investment and progress in FSHD research. Over recent years, multiple companies, academic institutions and research organisations have advanced programmes that seek to target the root causes of the disease.
The initiation of a first-in-human study is a significant step in the drug development process because it allows researchers to begin gathering information that cannot be obtained through laboratory or animal studies alone. While most investigational therapies do not ultimately reach regulatory approval, each clinical trial contributes important knowledge that helps advance the field.
Important limitations
Although this announcement is encouraging, it is important to recognise that the research remains at an early stage.
DYNE-302 has not yet generated human efficacy data, meaning there is currently no evidence that it improves muscle strength, physical function or quality of life in people living with FSHD. The upcoming study is primarily designed to assess safety and to collect early information about the therapy in humans.
In addition, the initial participant cohort is small, involving only nine individuals. Findings from early-stage studies must be interpreted cautiously and will need to be confirmed through larger and longer clinical trials.
Next steps
The next milestone will be the launch of the Phase 1 study and the enrolment of participants. Researchers will then gather safety and dosing information before determining whether DYNE-302 should progress into later-stage clinical development.
Future trial results will help determine whether reducing DUX4 activity can translate into meaningful clinical benefits for people living with FSHD.
While this development represents an important step forward in FSHD research, further clinical studies will be needed to determine whether the investigational therapy can deliver meaningful benefits for people living with FSHD.
Learn more